Chao Li

Title: Innovations of Chao Li in Glycoprotein Research

Introduction

Chao Li is an accomplished inventor based in College Park, MD (US). He has made significant contributions to the field of glycoprotein research, particularly through his innovative patent that focuses on fucosidase mutants. His work has implications for drug delivery and vaccine development, showcasing the potential of his inventions in therapeutic applications.

Latest Patents

Chao Li holds a patent titled "Designer α 6-fucosidase mutants enable direct core fucosylation of intact N-glycopeptides and N-glycoproteins." This invention introduces novel fucosidase mutants that serve as fuco-ligases for core fucosylation of various biological glycopeptides and glycoproteins, including intact therapeutic antibodies. The patent highlights several mutants with mutations at the general acid/base residue E274 of the α1,6-fucosidase, such as E274A, E274S, and E274G, which efficiently fucosylate a wide variety of complex N-glycopeptides and intact glycoproteins. These site-specific mutants enable the transfer of fucose to a core GlcNAc-Asn residue, making them useful for advancements in drug delivery and vaccine development.

Career Highlights

Chao Li is affiliated with the University System of Maryland, where he continues to engage in groundbreaking research. His work has not only contributed to the scientific community but has also paved the way for practical applications in medicine and biotechnology.

Collaborations

Chao Li has collaborated with notable colleagues, including Lai-Xi Wang and Shilei Zhu. These partnerships have enhanced the scope and impact of his research, fostering an environment of innovation and discovery.

Conclusion

Chao Li's contributions to glycoprotein research through his patented inventions demonstrate his commitment to advancing science and technology. His work holds promise for significant advancements in therapeutic applications, particularly in drug delivery and vaccine development.